32 results about "Metformin hcl" patented technology

The invention belongs to the technical field of pharmaceutical preparations, relates to a metformin hydrochloride sustained-release tablet and a preparation method thereof, and aims to overcome the technical defects of insufficient release behavior regulation and control precision and poor stability of an existing metformin hydrochloride sustained-release preparation. The metformin hydrochloride sustained-release tablet disclosed by the invention takes metformin hydrochloride as an effective component, is matched with sustained-release materials including hydroxypropyl methyl cellulose, propylene carbonate, zein, a filling agent, an adhesive and a lubricating agent, and can be selectively matched with a gastric-soluble film coating material. According to the invention, the stable release of the medicine is realized, the initial burst release phenomenon is avoided, meanwhile, the stability of the preparation is remarkably improved, and the good slow release performance can still be maintained after long-term storage.

The application discloses a baicalin ternary co-amorphous drug and a preparation method and application thereof, and the amorphous substance can effectively improve the solubility and dissolution of puerarin and baicalin. The application mixes metformin hydrochloride, puerarin and baicalin according to a molar ratio of 1:1:1, and obtains the baicalin ternary co-amorphous drug through a ball milling method or a solvent-assisted milling method, the preparation method is green and efficient, the co-amorphous substance has high light stability and thermal stability, the solubility is increased by 1.7 times compared with that of a puerarin raw drug crystal, the solubility is increased by 46.8 times compared with that of a baicalin raw drug crystal, and the solubility is reduced by 14.8 times compared with that of a metformin hydrochloride raw drug crystal. The baicalin ternary co-amorphous drug has certain application prospects in liver protection, blood sugar reduction, treatment of damp-heat type colitis and cervical cancer.

The utility model discloses a metformin hydrochloride electrochemical analysis device which comprises a shell, and one side of the shell is provided with an electric sensor interface; the power supply unit is arranged in the shell and is used for generating polarization voltage; the silk-screen printing electrode electric sensor is electrically connected with the power supply unit and comprises a flexible electrode base body, a working electrode, a counter electrode, a reference electrode, an insulating layer, a wiring terminal and an electrode connecting wire, and the working electrode, the counter electrode, the reference electrode, the insulating layer, the wiring terminal and the electrode connecting wire are arranged on the flexible electrode base body; the surface of the working electrode is modified with an imprinted polymer with selective recognition on metformin hydrochloride; the signal processing unit is arranged in the shell and comprises a shunt resistor, an operational amplifier, a signal converter, a data storage chip and a microprocessor which are electrically connected in sequence; the display screen is electrically connected with the microprocessor and is used for displaying the converted concentration value; the method has the advantages that the metformin hydrochloride can be rapidly and accurately detected, and the use is relatively convenient.

The invention provides a sitagliptin and metformin sustained-release pharmaceutical composition as well as a preparation method and application thereof, and relates to the technical field of sustained-release preparations. The pharmaceutical composition comprises a sustained-release tablet core and a quick-release coating layer, the sustained-release tablet core comprises an active ingredient metformin hydrochloride and a sustained-release framework material hydroxypropyl methylcellulose, and the sustained-release tablet core does not contain microcrystalline cellulose; the quick-release coating layer comprises an active component sitagliptin phosphate; the weight ratio of metformin hydrochloride to hydroxypropyl methylcellulose in the sustained release tablet core is 50: (24-27). The composition utilizes a double-layer structure to realize double-phase release of the medicine; the microcrystalline cellulose is removed, and the specific ratio of the active component to the framework material is limited, so that the moldability and ideal dissolution behavior of the preparation are ensured while the tablet weight is remarkably reduced to improve the swallowing compliance, and the technical problem that the slow-release framework function is difficult to maintain under the condition that the weight of a high-drug-loading-capacity compound preparation is greatly reduced is successfully solved.

The present invention relates to a film coated tablet comprising empagliflozin and metformin hydrochloride, wherein comprising at least one binder which is hydroxypropyl methyl cellulose or hydroxypropyl cellulose or mixtures thereof, the tablet provides pharmacotechnical properties and the desired dissolution profile. The present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient method of preparing the tablet.

The application provides a sitagliptin and metformin hydrochloride sustained-release pharmaceutical composition and a preparation method and application thereof, and relates to the technical field of sustained-release preparations. The pharmaceutical composition comprises a sustained-release tablet core and a quick-release coating layer; the sustained-release tablet core comprises active ingredients metformin hydrochloride and a sustained-release matrix material hydroxypropyl methyl cellulose, and the sustained-release tablet core does not contain microcrystalline cellulose; the quick-release coating layer comprises active ingredients sitagliptin phosphate; the weight ratio of metformin hydrochloride to hydroxypropyl methyl cellulose in the sustained-release tablet core is 50:(24-27). The composition realizes double-phase release of drugs by using a double-layer structure; by removing the microcrystalline cellulose and limiting the specific ratio of active ingredients to the matrix material, the forming property of the preparation and the ideal dissolution behavior are ensured while the tablet weight is significantly reduced to improve the swallowing compliance, and the technical problem that a high drug loading compound preparation is difficult to maintain the function of the sustained-release matrix under a large amount of weight reduction is successfully solved.

The invention discloses a terbium-doped benzene polycarboxylic acid-metformin HOF material and application thereof in detection of an explosive precursor sodium hypochlorite, and belongs to the technical field of fluorescent probes and fluorescence detection. The terbium-doped benzene polycarboxylic acid-metformin HOF material is formed by coordination compounding of an HOF matrix and rare earth metal ions Tb < 3 + >, and the HOF matrix is formed by self-assembly of benzene polycarboxylic acid compounds and metformin hydrochloride through intermolecular hydrogen bonds. The material can generate high-selectivity fluorescence quenching response to sodium hypochlorite (NaClO) through characteristic fluorescence emission (5D4-7F5 transition) of Tb < 3 + > at 545nm, is low in detection limit and wide in linear range, and can be used for realizing rapid and high-sensitivity detection of low-concentration NaClO. And the method has great significance in blocking the synthesis of explosives based on NaClO.

The invention provides a novel metformin hydrochloride enteric-coated preparation, which is an oral dosage form prepared from a therapeutically effective amount of biguanide compound and pharmaceutically acceptable auxiliary materials, and is characterized in that the dissolution rate of metformin hydrochloride in a medium with the pH value of 4.5 within 120 minutes is not higher than 15%; and the dissolution rate of metformin hydrochloride in a medium with the pH value of 6.8 within 20 minutes is not lower than 85%, preferably, the dissolution rate in a medium with the pH value of 4.5 within 120 minutes is not higher than 7.5%, and the dissolution rate in a medium with the pH value of 6.8 within 15 minutes is not lower than 85%. The metformin hydrochloride enteric-coated preparation meeting the technical requirements of medicine dissolution improves the gastrointestinal tract tolerance of metformin hydrochloride and reduces adverse reactions caused by medicines under the condition that the hypoglycemic curative effect is not reduced or even improved, can be taken before meals, and can also be taken after meals or during meals, so that the metformin hydrochloride enteric-coated preparation is suitable for clinical application. The medicine taking compliance of a patient is improved.

The application provides a method for simultaneously determining the content of dapagliflozin and metformin, which adopts a reverse-phase high performance liquid chromatography method to separate and determine the content of dapagliflozin and metformin in dapagliflozin and metformin sustained-release tablets. The method has good separation degree, solvent does not interfere with detection, and good method specificity. The detection method is simple, rapid, accurate, high in sensitivity, good in repeatability and accuracy, can quickly and accurately perform qualitative and quantitative analysis on the content of dapagliflozin and metformin hydrochloride in dapagliflozin and metformin sustained-release tablets, and ensures the controllability of the quality of the product.

This invention provides a method for preparing a metformin compound hypoglycemic oral solution, relating to the pharmaceutical field, comprising: step S1, pretreatment of traditional Chinese medicine components; step S2, enzymatic hydrolysis of the first group of traditional Chinese medicine components; step S3, supercritical extraction; step S4, preparation of mixed traditional Chinese medicines; step S5, preparation of inclusion complex; step S6, compound formulation; and step S7, post-processing. This method synergistically combines extracts from seven traditional Chinese medicines—bitter melon, phellodendron bark, astragalus root, kudzu root, rehmannia root, ginseng, and privet fruit—with metformin hydrochloride to form a metformin compound hypoglycemic oral solution, balancing the synergy, safety, and stability of traditional Chinese and Western medicines, thereby improving hypoglycemic effects while reducing the incidence of gastrointestinal adverse reactions to metformin.

The invention discloses a self-generating controlled-drug-release surgical suture for promoting healing of diabetic wounds and a preparation method and application of the self-generating controlled-drug-release surgical suture. The preparation method comprises the following steps: respectively preparing PVDF and PLLA nanofibers through an electrostatic spinning process, curling a nanofiber membrane by taking the PVDF fibers as an inner core until the surface of the nanofiber membrane is completely covered with one or more layers of PLLA nanofibers, and then enhancing the fiber orientation and mechanical strength through hot stretching to obtain the composite fiber inner core with excellent performance and piezoelectric effect. The silk fibroin solution and the sodium alginate solution are mixed, metformin hydrochloride is added, the mixture is evenly mixed and then coated on the composite fiber inner core, and finally the absorbable surgical suture with the metformin-loaded sodium alginate / silk fibroin gel coating is obtained through ionic crosslinking treatment. The suture has the triple functions of mechanical suture, electrical stimulation treatment and drug controlled release, can remarkably improve the closing speed and healing quality of diabetic wound surfaces, and has a wide application prospect.

The invention belongs to the technical field of drug crystallization, and provides metformin hydrochloride and fenofibrate double-drug-loading particles and a preparation method thereof.The preparation method comprises the following steps that polysaccharide, a solvent I and metformin hydrochloride are mixed and heated, and a homogeneous solution is obtained; mixing the homogeneous solution, fenofibrate and triglyceride to obtain a suspension; a cross-linking agent, a solvent II and the suspension are mixed and placed in a crystallizer to be subjected to a crystallization reaction, and a crystallization solution is obtained; and carrying out solid-liquid separation on the crystallization liquid, washing, and drying to obtain the double-drug-loading particles. The obtained particles are in a solid state and have good stability compared with a micelle drug loading system, meanwhile, the operation unit is simplified by adopting an in-situ crystallization means in the carrier, operation such as mixing, grinding and spray drying is not needed, needed equipment is simple, operation is easy and convenient, and good technical economy and high application value are achieved.

1. The name of the design product: packaging box (metformin hydrochloride sustained-release tablets). 2. The use of the design product: for product packaging. 3. The design features of the design product: the combination of shape and pattern. 4. The picture or photo that best indicates the design features: front view.

The present invention relates to a film coated tablet comprising empagliflozin and metformin hydrochloride, wherein comprising at least two fillers and the amount of fillers is 10.0% to 60.0% by weight in the total composition, the tablet provides the desired stability and pharmacotechnical properties and the desired dissolution profile. The present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient method of preparing the tablet.

The invention discloses a nicotinoyl metformin crystal form and a preparation method thereof. According to the nicotinoyl metformin crystal form shown in the formula I provided by the invention, in an X-ray powder diffraction pattern, at least three characteristic peaks exist at the diffraction angles of 10.64 + / -0.2 degrees, 11.42 + / -0.2 degrees, 15.18 + / -0.2 degrees, 16.06 + / -0.2 degrees, 16.44 + / -0.2 degrees and 25.22 + / -0.2 degrees, which are represented by 2 theta. The invention also provides a preparation method, which comprises the following steps: 1) dissolving metformin hydrochloride and ethyl nicotinate in an organic solvent in an inert gas atmosphere to form a solution 1; dissolving an organic metal strong base catalyst in an organic solvent to form a solution 2; and 2) dropwise adding the solution 2 into the solution 1 while stirring, reacting, pouring the reacted solution into ice water after the reaction is finished, filtering, washing, and drying to obtain the nicotinoyl metformin crystal form. The crystal form parameters of the nicotinoyl metformin are obtained for the first time, and the nicotinoyl metformin has high purity, high stability and low hygroscopicity; the preparation method can directly obtain the nicotinoyl metformin crystal form, and is simple, high in yield, simple in post-treatment and efficient in preparation.

The application discloses a novel dental nanocomposite material and a preparation method and application thereof, and the nanocomposite material comprises the following preparation raw materials in parts by weight: 15-30 parts of eucommia ulmoides derived antibacterial carbon dots-epigallocatechin gallate, 10-25 parts of iron nitrate, 5-7 parts of boric acid, 8-12 parts of metformin hydrochloride, 4-6.6 parts of zinc chloride, 40-60 parts of hyaluronic acid and 4-6 parts of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid sodium. The application takes eucommia ulmoides derived antibacterial carbon dots-epigallocatechin gallate as a core, and through the o-benzenetriol structure of epigallocatechin gallate, a stable metal-phenol / boric acid ester hybrid network inner shell is cooperatively constructed with iron ions and boric acid, and the effect of synergistically improving anti-inflammatory and long-acting promotion of directional differentiation of dental pulp stem cells is achieved.

The invention relates to the field of pharmaceutical preparations, and particularly discloses a metformin hydrochloride tablet and a preparation method thereof. The method comprises the following steps: carrying out low-temperature crushing, graded screening and pre-drying treatment on a metformin hydrochloride raw material medicine to obtain a pretreated raw material; mixing the pretreated raw materials with auxiliary materials, and sequentially carrying out semi-dry granulation and fluidized bed granulation to obtain porous particles; drying the porous particles, mixing the dried porous particles with a lubricant, and tabletting to obtain a plain tablet; and coating the tablets by adopting a fluidized bed bottom spraying process. Wherein when the enteric-coated tablet is prepared, a coating solution containing acrylic resin, a plasticizer and a pore-foaming agent is adopted. According to the invention, the contradiction between particle strength and high porosity is synergistically solved through a composite granulation process, so that the tablet disintegrates rapidly and is dissolved out completely; the reliable protection of the enteric-coated tablet in the stomach and the rapid release of the enteric-coated tablet in the intestine are realized through a precise coating process, and the gastrointestinal tract stimulation risk is remarkably reduced.

The application relates to the field of metformin hydrochloride sustained-release tablets, and discloses a metformin tablet pressing machine which comprises an operation table, a lower mold mechanism is slidably connected to the upper surface of the operation table, an upper mold mechanism is fixedly installed on the left side of the upper surface of the operation table and located on the left side of the lower mold mechanism, a discharging mechanism is fixedly installed on the left side of the upper surface of the operation table and located on the left side of the upper mold mechanism, and a feeding mechanism is fixedly installed on the right side of the upper surface of the operation table and located on the right side of the lower mold mechanism. The lower mold mechanism and the auxiliary plate are arranged, the formed tablets can be separated from the lower mold mechanism, the tablets formed on the lower mold mechanism can be effectively scraped off from the lower mold mechanism, the subsequent collection work is facilitated, the upper mold mechanism can effectively extrude and form the medicine raw materials on the lower mold mechanism.

1. Name of the product in this design: Outer packaging box for medicine (metformin hydrochloride sustained-release tablets). 2. Purpose of this design: For use in the outer packaging of solid medicines. 3. The key design elements of this product are the combination of shape, pattern, and color. 4. The image or photograph that best illustrates the design's key points: a 3D model. 5. The design for which protection is sought includes color. 6. The rear view is the same as the front view, so the rear view is omitted.

The application discloses a raw material smashing device for metformin hydrochloride sustained-release tablet production and relates to the technical field of smashing processing. The raw material smashing device comprises a smashing assembly which is used for smashing raw materials, and a fixing assembly and a pre-installation assembly are arranged in the smashing assembly. When the raw material smashing device is used, the smashing hammer is pre-installed through the pre-installation assembly, a hydraulic rod is started, a moving rod is pulled to move to the left side, the fixed plate and the fixed rod are driven to move together, the L-shaped rod is in contact with the fixed plate on the right side, the L-shaped rod is driven to be inserted into the clamping hole, the fixed plate on the right side limits the L-shaped rod, the L-shaped rod limits the connecting rod, the smashing hammer is limited, and multiple hammer heads are quickly installed and fixed under the cooperation of the fixing assembly and the pre-installation assembly, so that the bolts are not required to be installed one by one, the bolts are prevented from being loosened and falling off due to impact force, and the hammer heads are prevented from being loosened.

The application discloses a nano drug based on nitrogen-doped selenized carbon dots and a preparation method and application thereof, and belongs to the technical field of biological medicines, wherein the preparation method of the nano drug comprises the following steps: placing an amino acid compound and a small molecule drug in a solvent to mix, adjusting the pH value to be alkaline, then performing a heating reaction to obtain a reaction solution; the amino acid compound is one or more of L-selenocystine, L-selenocysteine and L-selenomethionine; the small molecule drug is metformin hydrochloride or phenformin; and the nano drug is obtained by separating and purifying from the reaction solution. The nano drug can significantly relieve cell oxidative damage induced by hydrogen peroxide, can effectively remove ROS excessively accumulated in a damage site, and can inhibit the progress of secondary damage. In addition, the nano drug can regulate four key signal paths of antioxidation, anti-inflammation, anti-apoptosis and axon regeneration and myelination, and can synergistically promote the nerve repair process after spinal cord injury.

The invention provides a targeted intestinal flora small molecule medicine and application thereof in treatment of type II diabetes mellitus, the medicine is prepared from traditional Chinese medicine active ingredients, chemical active ingredients, bioactive peptides and active probiotics according to a specific proportion, the chemical effective component is a metformin hydrochloride and prebiotic compound, the bioactive peptide comprises gamma-glutamyl peptide and ovalbumin hypoglycemic peptide, and the active probiotic is freeze-dried powder of ackermania muciniphila with high activity. The preparation method comprises the steps of pretreatment, step-by-step mixing, granulation and drying, can regulate the balance of intestinal flora, improve insulin resistance and repair the intestinal barrier function, and can be used for treating or preventing type II diabetes mellitus.

The utility model relates to the technical field of pharmaceutical production, concretely relates to a production equipment of metformin hydrochloride sustained-release tablet, including stirring mechanism and mixing subassembly, the stirring mechanism includes support frame, and the inner wall fixed connection of support frame has the cylinder, the inner wall fixed connection of support frame has the connecting frame, and the inner wall fixed mounting of connecting frame has the blanking assembly, the blanking assembly includes the blanking seat fixed connection on the connecting frame, and the inside of blanking seat is provided with the circular cavity, the inner wall of circular cavity is provided with feed port and discharge port respectively, the blanking seat is linked together through feed port and cylinder. The utility model overcomes the deficiency of prior art, through setting up blanking assembly between stirring mechanism and mixing subassembly, the cooperation between blanking assembly and motor, conveniently convey the smashing raw materials in the cylinder to the mixing cylinder, the blanking assembly can adjust the rate of raw material delivery, and then avoid the problem that raw materials appear to jam in the process of cylinder blanking.

The invention discloses a preparation method and application of drug-loaded metformin carbon dots, and the preparation method comprises the following steps: synthesizing fluorescent carbon MCDs by using metformin hydrochloride and glycine as precursors through a hydrothermal method, further carrying out PDA wrapping, and realizing loading of DEX through PDA to prepare a nano system MCDs-PDA (at) DEX. The nano material can be taken by hiPSCs and has good biocompatibility, experimental results prove that the prepared nano material can induce osteogenic differentiation of the hiPSCs, and an MCDs-PDA (at) DEX / GG hydrogel system prepared on the basis of the material has a remarkable bone defect repair effect, so that a new direction and basis are provided for development of bone tissue repair related materials.

The invention belongs to the technical field of medical chemical synthesis, and particularly relates to a synthetic method and a synthetic device of metformin hydrochloride. A dimethylamine aqueous solution and dicyandiamide are used as reaction raw materials, a small amount of water is used as a solvent, the dimethylamine aqueous solution, dicyandiamide and water are fully mixed firstly, then excessive hydrogen chloride solution or hydrogen chloride gas is introduced, and a reaction is performed at 150-250 DEG C, so that the reaction is more sufficient, the reaction efficiency is higher, the reaction time is shortened, and the yield is increased. And the ideal yield of metformin hydrochloride is obtained. Experiments show that the yield of metformin hydrochloride can be increased to 90% or above, and the reaction time can be shortened to be within 60 min.

1. The name of the design product: packaging box (metformin hydrochloride sustained-release tablets). 2. The use of the design product: for product packaging. 3. The design features of the design product: the combination of shape and pattern. 4. The picture or photo that best indicates the design features: front view.

This invention discloses a metformin empagliflozin tablet technical field, specifically a metformin empagliflozin tablet and its fluidized bed preparation process. First, copovidone is added to purified water to prepare a copovidone aqueous solution. Then, metformin hydrochloride, empagliflozin, and corn starch are added to a mixing device for mixing to obtain a premix. Next, the premix is ​​transferred to a fluidized bed device for fluidization, while the copovidone aqueous solution is sprayed in for granulation, and then dried to the target moisture content to obtain dry granules. The dry granules are then mixed with magnesium stearate and silica to obtain a final mixture. Based on this, this invention, by employing fluidized bed granulation and precisely controlling the process parameters throughout the entire process, including premixing, binder preparation, fluidized bed granulation, final mixing, and coating, achieves a robust and controllable preparation process suitable for large-scale production.

This application discloses a terbium-doped benzenepolycarboxylic acid-bismethylguanidine (HOF) material and its application in the detection of the explosive precursor sodium hypochlorite, belonging to the field of fluorescent probes and fluorescent detection technology. This terbium-doped benzenepolycarboxylic acid-bismethylguanidine (HOF) material consists of an HOF matrix and rare earth metal ions (Tb). 3+ The HOF matrix is ​​composed of a coordination complex and is constructed from a benzene polycarboxylic acid compound and metformin hydrochloride through intermolecular hydrogen bonding self-assembly. This material can pass through Tb... 3+ Characteristic fluorescence emission at 545nm ( 5 D4→ 7 The F5 transition exhibits a highly selective fluorescence quenching response to sodium hypochlorite (NaClO), with a low detection limit and a wide linear range, enabling rapid and highly sensitive detection of low concentrations of NaClO. This is of great significance for blocking NaClO-based explosive synthesis.